MV BioTherapeutics

MV BioTherapeutics is a Swiss clinical-stage biotechnology company focused on developing innovative Live Biotherapeutic Products (LBPs) for oncology and infectious diseases. The company's proprietary MV-Vax platform utilizes non-genetically modified bacteria to induce potent mucosal and systemic immune responses. Their lead candidate is being developed for the treatment of non-muscle invasive bladder cancer as a potentially safer and more effective alternative to current standard-of-care treatments like BCG. Additionally, the company has advanced a mucosal vaccine candidate for COVID-19 into early clinical testing. MV BioTherapeutics aims to revolutionize immunotherapy by leveraging the natural symbiotic relationship between microbes and the human immune system.